

Multiple myeloma treatments

Reference Number: RDF2481-24

Date of Response: 23/04/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which. 72 Patients.

Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:

	Patients
<i>Belantamab Mafodotin [Blenrep]</i>	0
<i>Bortezomib [Velcade] monotherapy or with dexamethasone</i>	0
<i>Bortezomib, thalidomide and dexamethasone [VTD]</i>	0
<i>Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)</i>	* <5
<i>Carfilzomib [Kyprolis] and dexamethasone</i>	0
<i>Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone</i>	* <5
<i>Daratumumab [Darzalex] monotherapy</i>	* <5
<i>Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)</i>	* <5
<i>Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)</i>	11
<i>Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone</i>	0
<i>Elranatamab</i>	0
<i>Idecabtagene vicleucel [Abecma]</i>	0
<i>Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)</i>	* <5
<i>Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)</i>	* <5
<i>Lenalidomide [Revlimid] monotherapy</i>	7
<i>Lenalidomide [Revlimid] and dexamethasone</i>	13
<i>Pomalidomide [Imnovid] and dexamethasone</i>	* <5
<i>Selinexor and dexamethasone</i>	0
<i>Talquetamab</i>	0
<i>Teclistamab [Tecvayli]</i>	0
<i>Any other systemic anti-cancer therapy</i>	11

*<5 - Section 40 (2)

Please note that in accordance with Section 40 (2) where activity is 5 or less than 5, the Trust is unable to provide the exact information. We consider the data exempt on the following grounds:

The Trust considers that disclosure of the information risks identifying individuals. The reason for this is that the number of patients for which this applies is very low.

This and the fact that the data requested relates to the RDUH Health NHS Trust only and therefore relates to patients treated in a specific location (rather than covering a larger geographical area), increases the risk of identification or self-identification.

The Trust's view is that s.40(2) is applicable because disclosure of information which could lead to a patient being identified would be a breach of the patient's rights under the Data Protection Act Data Protection Principles set out in Schedule 1 of the GDPR, namely Principle 1.